Skip to main content
Explore URMC

menu

Study of Arimoclomol in Inclusion Body Myositis (IBM)

Basic Study Information

Purpose:
Funding Source - FDA OOPD. The purpose of this study is to evaluate the safety and efficacy of the study drug, Arimoclomol in IBM patients.

Location: University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher: Elizabeth Luebbe

Study Contact Information

Study Coordinator: Liz Luebbe
Phone: 585-275-7867
Email: elizabeth_luebbe@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search